Another Vertex investor conference presentation at the Bernstein sponsored event next Wednesday. May include an update on CF study enrollment progress for Phase 3 809/770 and Phase 3 770 monotherapy clinical trials to expand treatable CF population with CFTR corrector and potentiator drugs. Also timetable for initiation of Phase two clinical trials using VX 135. Lastly possible discussion of collaborations for development of VX 787 and VX 509 with larger Pharma. Looking forward to some new information regarding progress on the promising Vertex pipeline..